Compounds useful as inhibitors of ATR kinase

Patent metadata

Field	Value
Publication number	US-9334244-B2
Application number	US-201113106184-A
Country	US
Kind code	B2
Filing date	May 12, 2011
Priority date	May 12, 2010
Publication date	May 10, 2016
Grant date	May 10, 2016

Abstract

The present invention relates to pyrazine and pyridine compounds useful as inhibitors of ATR protein kinase. The invention also relates to pharmaceutically acceptable compositions comprising the compounds of this invention; methods of treating various diseases, disorders, and conditions using the compounds of this invention; processes for preparing the compounds of this invention; intermediates for the preparation of the compounds of this invention; and methods of using the compounds in in vitro applications, such as the study of kinases in biological and pathological phenomena; the study of intracellular signal transduction pathways mediated by such kinases; and the comparative evaluation of new kinase inhibitors.
The compounds of this invention have formula IV:

wherein the variables are as defined herein.

First claim

The invention claimed is:

1. A compound of formula IV:

or a pharmaceutically acceptable salt thereof, wherein
R 3 is H or methyl;
A is N;
R 2 is phenyl optionally substituted with 1-4 J Q groups;
J Q is SO 2 (C 1-4 alkyl) or CO(C 1-4 alkyl);
L is C 2 aliphatic, —C(O)NH—, —C(O)N(C 1-6 alkyl)—;
n is 0 or 1;
R 1 is a 5-6 membered monocyclic aryl or heteroaryl ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur; wherein said monocyclic aryl or heteroaryl ring is optionally fused to another ring to form a 8-10 membered bicyclic aryl or heteroaryl ring having 0-6 heteroatoms independently selected from nitrogen, oxygen, or sulfur; R 1 is optionally substituted with 1-5 J 1 groups;
J 1 is halo, —CN, —NO 2 , V—R, or —(V 2 ) m -Q 3 ;
V is a C 1-10 aliphatic chain wherein 0-3 methylene units are optionally and independently replaced with oxygen, nitrogen, sulfur, C(O), S(O), or S(O) 2 ; V is optionally substituted with 1-6 occurrences of J v ;
V 2 is a C 1-10 aliphatic chain wherein 0-3 methylene units are optionally and independently replaced with oxygen, nitrogen, sulfur, C(O), S(O), or S(O) 2 ; V 2 is optionally substituted with 1-6 occurrences of J v2 ; m is 0 or 1;
Q 3 is a 3-8 membered saturated or unsaturated monocyclic ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or a 8-10 membered saturated or unsaturated bicyclic ring having 0-6 heteroatoms independently selected from nitrogen, oxygen, or sulfur; each Q 3 is optionally substituted with 1-5 J Q3 ;
each J v and J v2 is independently halogen, CN, NH 2 , NO 2 , C 1-4 aliphatic, NH(C 1-4 aliphatic), N(C 1-4 aliphatic) 2 , OH, O(C 1-4 aliphatic), CO 2 H, CO 2 (C 1-4 aliphatic), C(O)NH 2 , C(O)NH(C 1-4 aliphatic), C(O)N(C 1-4 aliphatic) 2 , NHCO(C 1-4 aliphatic), N(C 1-4 aliphatic)CO(C 1-4 aliphatic), SO 2 (C 1-4 aliphatic), NHSO 2 (C 1-4 aliphatic), or N(C 1-4 aliphatic)SO 2 (C 1-4 aliphatic), wherein said C 1-4 aliphatic is optionally substituted with halo;
each J Q3 is independently halo, oxo, CN, NO 2 , X—R, or —(X) p -Q 4 ,
p is 0 or 1;
X is C 1-10 aliphatic; wherein 1-3 methylene units of said C 1-6 aliphatic are optionally replaced with —NR, —O—, —S—, C(O), S(O) 2 , or S(O); wherein X is optionally and independently substituted with 1-4 occurrences of NH 2 , NH(C 1-4 aliphatic), N(C 1-4 aliphatic) 2 , halogen, C 1-4 aliphatic, OH, O(C 1-4 aliphatic), NO 2 , CN, CO(C 1-4 aliphatic), CO 2 H, CO 2 (C 1-4 aliphatic), C(O)NH 2 , C(O)NH(C 1-4 aliphatic), C(O)N(C 1-4 aliphatic) 2 , SO(C 1-4 aliphatic), SO 2 (C 1-4 aliphatic), SO 2 NH(C 1-4 aliphatic), SONH(C 1-4 aliphatic) 2 , NHC(O)(C 1-4 aliphatic), N(C 1-4 aliphatic)C(O)(C 1-4 aliphatic), NHS0 2 (C 1-4 aliphatic), or N(C 1-4 aliphatic)S0) 2 (C 1-4 aliphatic), wherein said C 1-4 aliphatic is optionally substituted with 1-3 occurrences of halo;
Q 4 is a 3-8 membered saturated or unsaturated monocyclic ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or a 8-10 membered saturated or unsaturated bicyclic ring having 0-6 heteroatoms independently selected from nitrogen, oxygen, or sulfur; each Q 4 is optionally substituted with 1-5 J Q4 ;
J Q4 is halo, CN, or C 1-4 alkyl wherein up to 2 methylene units are optionally replaced with O, N, S, C(O), S(O), or S(O) 2 ;
R is H or C 1-4 alkyl wherein said C 1-4 alkyl is optionally substituted with 1-4 halo.

2. The compound of claim 1 , wherein R 3 is methyl.

3. The compound of claim 1 , wherein R 3 is H.

4. The compound of claim 2 , wherein n is 0.

5. The compound of claim 4 , wherein R 1 is isoxazolyl or oxadiazolyl.

6. The compound of claim 5 , wherein R 1 is isoxazolyl.

7. The compound of claim 6 , wherein R 1 is optionally substituted with one occurrence of J 1 .

8. The compound of 7 , wherein J 1 is —(V 2 ) m -Q 3 .

9. The compound of claim 8 , wherein J 1 is phenyl.

10. The compound of claim 9 , wherein J 1 is phenyl optionally substituted with one occurrence of CH 2 NHCH 3 .

11. The compound of claim 2 , wherein n is 1.

12. The compound of claim 11 , wherein L is C(O)NH and R 1 is phenyl.

13. The compound of claim 1 , wherein R 3 is methyl or H; n is 0 or 1; L is CONH; R 1 is isoxazolyl or phenyl; J 1 is phenyl optionally substituted with one occurrence of CH 2 NHCH 3 ; and R 2 is phenyl optionally substituted with SO 2 (C 1-4 alkyl).

14. The compound of claim 1 selected from the following:

15. A pharmaceutical composition comprising a compound of claim 1 and a pharmaceutically acceptable carrier.

16. A method for inhibiting ATR in a patient comprising administering a compound of claim 1 or a pharmaceutically acceptable derivative thereof.

17. The method of claim 16 , further comprising administering to said patient an additional therapeutic agent selected from a DNA-damaging agent;
wherein said additional therapeutic agent is appropriate for a disease being treated;
and said additional therapeutic agent is administered together with said compound as a single dosage form or separately from said compound as part of a multiple dosage form.

18. The method of claim 17 , wherein said DNA-damaging agent is selected chemotherapy or radiation treatment.

19. A method of inhibiting ATR in a biological sample comprising contacting a compound of claim 1 with said biological sample.

Assignees

• Charrier Jean-Damien
• Durrant Steven John
• Knegtel Ronald Marcellus Alphonsus
• Virani Anisa Nizarali
• Reaper Philip Michael
• Vertex Pharma

Inventors

• Charrier Jean-Damien
• Durrant Steven John
• Knegtel Ronald Marcellus Alphonsus
• Virani Anisa Nizarali
• Reaper Philip Michael

Classifications

• A61K31/497

  containing further heterocyclic rings · CPC title

• C07D413/04

  directly linked by a ring-member-to-ring-member bond · CPC title

• C07D239/46 Primary

  Two or more oxygen, sulphur or nitrogen atoms · CPC title

• C07D241/24

  Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals · CPC title

• A61K31/4965 Primary

  Non-condensed pyrazines · CPC title